Trials / Completed
CompletedNCT00431444
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raloxifene | |
| DRUG | Zoledronic acid | |
| DRUG | Placebo oral pills | |
| DRUG | Placebo intravenous (i.v.) infusion |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-02-05
- Last updated
- 2011-03-29
- Results posted
- 2011-03-11
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00431444. Inclusion in this directory is not an endorsement.